Mannitol Βιοσερ (Mannitol)

Mannitol works by increasing the osmotic pressure of the extracellular fluid after intravenous infusion. This draws water from swollen brain tissue, the eye, and peripheral tissues into the vascular compartment, expanding plasma volume, enhancing renal filtration, and thereby reducing pressure in the affected compartments.

The dosage of Mannitol Βιοσερ is individualized and determined by the prescribing clinician based on the patient’s condition, weight, renal function, and therapeutic goals. Specific dosing regimens are not provided here and should follow the prescriber’s orders and local guidelines.

Safety data for Mannitol during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and decisions should be made by the treating physician.

To order Mannitol Βιοσερ, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Mannitol is a non‑ionic sugar alcohol that creates an osmotic gradient without being metabolized, making it effective for rapid fluid shifts. Compared with hypertonic saline, Mannitol provides a greater diuretic effect and is less likely to cause hypernatremia, but both require careful monitoring of electrolytes and fluid balance.

Mannitol intravenous solution should be stored at 2‑8 °C, kept refrigerated, protected from light, and never frozen. Before use, inspect the vial for particulate matter or discoloration, and allow the solution to reach room temperature if required for infusion, following aseptic technique.

Mannitol is administered by slow intravenous infusion, typically through a peripheral or central line. The infusion rate and total volume are set by the prescriber to achieve the desired osmotic effect while minimizing cardiovascular stress. Continuous monitoring of vital signs and urine output is recommended during administration.

Serious risks include pulmonary edema, severe dehydration, anaphylactic reactions, and cardiac arrhythmias. Patients should be monitored for signs of fluid overload, sudden drops in blood pressure, respiratory distress, and any allergic manifestations. Prompt medical intervention is required if any of these events occur.

Mannitol is contraindicated in patients with known hypersensitivity to mannitol, severe dehydration, active intracranial bleeding, uncontrolled heart failure, or severe renal impairment where fluid removal could worsen the condition. Clinicians should assess each patient’s medical history before initiating therapy.